The 2018 ASCO congress report includes the newest developments in clinical research and management of lung cancer that were presented at American Society of Clinical Oncology (ASCO) 2018 annual meeting, that was held in Chicago, USA.

Highlights include new data on therapies with PD-L1 inhibitors and EGFR-directed TKIs, recent benchmarks in the management of small-cell tumours, new insights on ALK-positive disease and expert interviews.

The memoinOncology Special Issue report is produced by Springer, as a supplement of memo (the Magazine of European Medical Oncology) and sponsored by Boehringer Ingelheim with an unrestricted educational grant. For more information on the memo inOncology Special Issue series, and for free access to all previous editions, visit the memo-inOncology website.

Access an articledirectly:

·        Preface

·        PD-(L)1inhibition alone and in combination: recent insights into immunotherapy

·        Immune checkpoint blockade: determinants of treatment success

·        New data on EGFR-directed TKIs across 3 generations

·        Interview with Barbara Melosky: “The sequencing question remains”

·        ALK-positive disease: pushing the borders of treatability

·        Recent benchmarks in the management of small-cell tumours

·        Comprehensive sequencing of plasma cell-free DNA permits non-invasive cancer detection

·        Distinct somatic genome variations in young lung cancer patients

Downloadthe full report (English)